Search - tctmd.com

Displaying 821 - 840 of 1143

Sort: Relevancy | Date

Presentation SCAI 2017

Watchman LAAO: Implant Procedure and Patient Management

Presenter: Chadi Alraies

May 11, 2017

Presentation Fellows 2017

LAA Closure: Data, Devices, and Technique

Presenter: Susheel Kodali, Mark Reisman

April 09, 2017

Presentation ECHO 2017

Interventional Echocardiography II: PVL and LAA Closure

Presenter: Omar K. Khalique

April 02, 2017

Presentation SIF 2017

LAA Closure: First or Second Line Therapy.

Presenter: Brij Maini

March 09, 2017

Presentation SIF 2017

LAA Closure with the WATCHMAN Device: A Perfect Case

Presenter: Ramon Quesada,

March 09, 2017

Presentation SIF 2017

Cardiac CTA for LAA Occlusion Planning and Follow Up

Presenter: Michael J. Rinaldi

March 08, 2017

Presentation JIM 2017

Clinical Experience With LAmbre LAA CLOSURE System

Presenter: Horst Sievert

February 09, 2017

Presentation TCT 2016

Management of Residual Leaks After LAA Closure

Presenter: David R. Holmes Jr., Jacqueline Saw

November 01, 2016

Presentation TCT 2016

Assessment and Implications of Residual Leaks After Percutaneous and Surgical LAA Closure

Presenter: David R. Holmes Jr., Jacqueline Saw

November 01, 2016

Presentation TCT 2016

Reimbursement Challenges For LAAC: Balancing The Clinical Need Vs. Robust Data Vs. Societal Economic Considerations

Presenter: Aaron V. Kaplan, Rachel Neubrander, Tamara Syrek Jensen

November 01, 2016

Presentation TCT 2016

Follow-up Evaluation After LAA Closure

Presenter: David R. Holmes Jr., Jacqueline Saw, Bushra S Rana

November 01, 2016

Presentation TCT 2016

Pivotal Trial Design Considerations: Noninferiority vs Superiority, Device, Control Arm Anticoagulation Durations, NOAC Considerations and More Industry and Clinician Perspectives

Presenter: Aaron V. Kaplan, Rachel Neubrander, Brian K. Whisenant

November 01, 2016

Presentation TCT 2016

Trial Designs For LAA Closure: Potential Regulatory Pathways and Unanswered Questions What FDA Would Like to See

Presenter: Aaron V. Kaplan, Rachel Neubrander, Katherine Wallon

November 01, 2016

Presentation TCT 2016

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Presenter: Martin W. Bergmann, Samir R. Kapadia, Harvey D. White

November 01, 2016

Presentation TCT 2016

Selecting the Right LAA Closure Device Based on Patient Characteristics and LAA Anatomy: Occluder, Ligation, or Clipping

Presenter: Martin W. Bergmann, Samir R. Kapadia, Jason H. Rogers

November 01, 2016

Presentation TCT 2016

Special Tips and Tricks for LAA Closure Using the Lariat

Presenter: Krzysztof Bartus, Randall J. Lee

November 01, 2016

Presentation TCT 2016

Special Tips and Tricks for LAA Closure Using the Lifetech LAA Occluder

Presenter: Krzysztof Bartus, Yat-Yin Lam

November 01, 2016

Presentation TCT 2016

Is LAA Closure an Alternative to Triple Therapy for all Patients or Those at High Bleeding Risk? Current Dataset

Presenter: Martin W. Bergmann, Samir R. Kapadia, Brian K. Whisenant

November 01, 2016

Presentation TCT 2016

Special Tips and Tricks for LAA Closure Using the Cardia LAA Occluder

Presenter: Krzysztof Bartus, Josep Rodés-Cabau

November 01, 2016

Presentation TCT 2016

Why Triple Therapy? Rationale and Potential Role for LAA Closure in the PCI Patient

Presenter: Martin W. Bergmann, Samir R. Kapadia, Ashish Pershad

November 01, 2016

Advertisement

Watchman LAAO: Implant Procedure and Patient Management

LAA Closure: Data, Devices, and Technique

Interventional Echocardiography II: PVL and LAA Closure

LAA Closure: First or Second Line Therapy.

LAA Closure with the WATCHMAN Device: A Perfect Case

Cardiac CTA for LAA Occlusion Planning and Follow Up

Clinical Experience With LAmbre LAA CLOSURE System

Management of Residual Leaks After LAA Closure

Assessment and Implications of Residual Leaks After Percutaneous and Surgical LAA Closure

Reimbursement Challenges For LAAC: Balancing The Clinical Need Vs. Robust Data Vs. Societal Economic Considerations

Follow-up Evaluation After LAA Closure

Pivotal Trial Design Considerations: Noninferiority vs Superiority, Device, Control Arm Anticoagulation Durations, NOAC Considerations and More Industry and Clinician Perspectives

Trial Designs For LAA Closure: Potential Regulatory Pathways and Unanswered Questions What FDA Would Like to See

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Selecting the Right LAA Closure Device Based on Patient Characteristics and LAA Anatomy: Occluder, Ligation, or Clipping

Special Tips and Tricks for LAA Closure Using the Lariat

Special Tips and Tricks for LAA Closure Using the Lifetech LAA Occluder

Is LAA Closure an Alternative to Triple Therapy for all Patients or Those at High Bleeding Risk? Current Dataset

Special Tips and Tricks for LAA Closure Using the Cardia LAA Occluder

Why Triple Therapy? Rationale and Potential Role for LAA Closure in the PCI Patient

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content